Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 7/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.56 |
| ▸ | CD44 | P16070 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29365632 | 1.00 | PNMT (1.00) | PNMTDRD2DRD3ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL65520 | 0.98 | PNMT (0.96) | PNMTDRD2DRD3ADRA2AADRA2B | |
| SCHEMBL1638541 | 0.92 | DRD2 (1.00) | PNMTDRD2DRD3ADRA2AADRA2B | |
| SCHEMBL29580085 | 0.92 | DRD2 (1.00) | PNMTDRD2DRD3ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL4224148 | 0.91 | DRD2 (0.96) | PNMTDRD2DRD3ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL30015379 | 0.91 | DRD2 (0.96) | PNMTDRD2DRD3ADRA2AADRA2B | |
| SCHEMBL24265588 | 0.89 | PNMT (0.80) | PNMTDRD2DRD3ADRA2AADRA2B | |
| SCHEMBL4033305 | 0.88 | PNMT (0.79) | PNMTDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL29642113 | 0.87 | PNMT (0.77) | PNMTDRD2DRD3ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL21753256 | 0.86 | PNMT (0.76) | PNMTDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110382475-A | NRF2 activator | 比奥根MA公司 | 2019-10-25 | — | — | CN | claimed |
| EP-1227803-B1 | COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS | BELLUS HEALTH INTERNATIONAL LTD (CH) | 2010-05-05 | — | — | EP | claimed |
| CN-100435785-C | Pharmaceutical use of IAPP inhibiting compounds or pharmaceutically acceptable esters or pharmaceutically acceptable salts thereof | UNIV KINGSTON (CH) | 2008-11-26 | — | — | CN | claimed |
| CN-101119969-A | Aryl and heteroaryl substituted tetrahydroisoquinolines and their use to block reuptake of norepinephrine, dopamine, and serotonin | AMR TECHNOLOGY INC (US) | 2008-02-06 | — | — | CN | claimed |
| US-6562836-B1 | Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 2003-05-13 | — | — | US | claimed |
| EP-4662208-A1 | COMPOUNDS AND COMPOSITIONS FOR SELECTIVE DEGRADATION OF ENGINEERED PROTEINS | Celgene Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4635494-A2 | AMIDO HETEROAROMATIC COMPOUNDS | Astrazeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| EP-4514782-B1 | AMIDO HETEROAROMATIC COMPOUNDS USEFUL IN THE TREATMENT OF LIVER DISEASES | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-12291524-B2 | Amido heteroaromatic compounds | ASTRAZENECA AB (SE) | 2025-05-06 | — | — | US | disclosed |
| US-20250011311-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2025-01-09 | — | — | US | disclosed |
| US-20240327381-A1 | Compounds and Compositions for Selective Degradation of Engineered Proteins | CELGENE CORPORATION (US) | 2024-10-03 | — | — | US | disclosed |
| EP-0528369-B1 | Cyclic imino derivatives, pharmaceutical compositions containing them and process for their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 1999-11-24 | — | — | EP | disclosed |
| EP-0922035-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998051671-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-19 | — | — | WO | disclosed |
| WO-1998050364-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998049145-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998006699-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 1998-02-19 | — | — | WO | disclosed |
| US-5455348-A | Anticoagulants | Thomae, Karl (DE) | 1995-10-03 | — | — | US | disclosed |
| EP-0528369-A2 | Cyclic imino derivatives, pharmaceutical compositions containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | PNMT 2892/4885DRD2 4762/4885DRD3 4682/4885 |
| US-12291524-B2 | Amido heteroaromatic compounds | CYP7A1, SLC10A1, CYP11B2 | PNMT 1499/4885DRD2 3230/4885DRD3 2843/4885 |
| US-20240327381-A1 | Compounds and Compositions for Selective Degradation of Engineered Proteins | TP53, APC, MDM2 | PNMT 3596/4885DRD2 4828/4885DRD3 4820/4885 |
| US-20250011311-A1 | AMIDO HETEROAROMATIC COMPOUNDS | CYP7A1, SLC10A1, CYP11B2 | PNMT 1499/4885DRD2 3230/4885DRD3 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.